ONC-841 

ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Siglec-10

ONC-841 promotes phagocytosis of amyloid-β and Tau aggregates by IPS-derived human microglia and mouse primary microglia^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

The mouse IgG isotype clone (31F11) of ONC-841 (intravenous injection; 6.5 weeks) clears cerebral β-amyloid plaques, reduces plasma pTau181 and total Tau biomarker levels, and restores microglial function, thereby counteracting AD pathogenesis in two Alzheimer's disease transgenic mouse models expressing human SIGLEC10^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

89790  [NCBI]

Q96LC7

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.08 kDa

Liquid

Colorless to light yellow

[ONC-841]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized Siglec-10-hFc can bind ONC-841. The EC₅₀ for this effect is 34.77 ng/mL.

• [1]. Wang P, et al. Therapeutic activities of anti‐human SIGLEC10 mAb in Multiple Transgenic Mouse AD Models. Alzheimer's & Dementia. 2025 Dec;21:e101818.
  

  [2]. Sobczak K, et al. The unique molecular recognition features of Siglec-10: structural insights into sialoglycan and antibody interactions. bioRxiv. 2025 Jun 10:2025-06.